Table 4.
Pathology-stratified analysis of post-EMR bleeding risk.
| Pathology group | n | Bleeding n (%) | Crude OR (95% CI) | Crude P | Adjusted OR* (95% CI) | Adjusted P* |
|---|---|---|---|---|---|---|
| Neither HRA nor HRSP | 1,302 | 16 (1.23) | 1.00 | — | 1.00 | — |
| HRA only | 2,368 | 72 (3.04) | 2.52 (1.46–4.35) | <0.001 | 2.90 (1.66–5.07) | <0.001 |
| HRSP only | 101 | 3 (2.97) | 2.46 (0.70–8.59) | 0.158 | 2.27 (0.64–8.01) | 0.202 |
| Both HRA + HRSP | 264 | 15 (5.68) | 4.84 (2.36–9.92) | <0.001 | 5.54 (2.67–11.49) | <0.001 |
*Adjusted for age, sex, BMI, diabetes, hypertension, anticoagulant/antiplatelet use, and CKD stages 2–5 (not adjusted for polyp size or count).